RU2749025C2 - Лечение рака при помощи tg02 - Google Patents

Лечение рака при помощи tg02 Download PDF

Info

Publication number
RU2749025C2
RU2749025C2 RU2018137217A RU2018137217A RU2749025C2 RU 2749025 C2 RU2749025 C2 RU 2749025C2 RU 2018137217 A RU2018137217 A RU 2018137217A RU 2018137217 A RU2018137217 A RU 2018137217A RU 2749025 C2 RU2749025 C2 RU 2749025C2
Authority
RU
Russia
Prior art keywords
cancer
cell
carcinoma
tumor
inhibitor
Prior art date
Application number
RU2018137217A
Other languages
English (en)
Russian (ru)
Other versions
RU2018137217A (ru
RU2018137217A3 (https=
Inventor
Томас М. Эсток
Экард Вебер
Трэйси ПЭРРОТТ
Original Assignee
Трагара Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Трагара Фармасьютикалз, Инк. filed Critical Трагара Фармасьютикалз, Инк.
Publication of RU2018137217A publication Critical patent/RU2018137217A/ru
Publication of RU2018137217A3 publication Critical patent/RU2018137217A3/ru
Application granted granted Critical
Publication of RU2749025C2 publication Critical patent/RU2749025C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018137217A 2016-03-24 2017-03-24 Лечение рака при помощи tg02 RU2749025C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662312712P 2016-03-24 2016-03-24
US62/312,712 2016-03-24
US201662423468P 2016-11-17 2016-11-17
US62/423,468 2016-11-17
PCT/US2017/023965 WO2017165732A1 (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02

Publications (3)

Publication Number Publication Date
RU2018137217A RU2018137217A (ru) 2020-04-24
RU2018137217A3 RU2018137217A3 (https=) 2020-05-29
RU2749025C2 true RU2749025C2 (ru) 2021-06-03

Family

ID=59899752

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018137217A RU2749025C2 (ru) 2016-03-24 2017-03-24 Лечение рака при помощи tg02

Country Status (12)

Country Link
US (2) US11865116B2 (https=)
EP (1) EP3432888B1 (https=)
JP (2) JP7026299B2 (https=)
KR (2) KR102491013B1 (https=)
CN (2) CN109195603B (https=)
AU (1) AU2017238647B2 (https=)
ES (1) ES2941687T3 (https=)
IL (1) IL261959B2 (https=)
MX (3) MX387283B (https=)
RU (1) RU2749025C2 (https=)
SG (2) SG11201808306PA (https=)
WO (1) WO2017165732A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02
KR20220004025A (ko) * 2019-03-18 2022-01-11 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 종양-선택적 병용 요법
JP7684910B2 (ja) * 2019-04-22 2025-05-28 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 小児対象において神経膠腫を治療するためのｔｇ０２の使用
WO2021155580A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating cancer
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
US20230287510A1 (en) * 2020-08-10 2023-09-14 The Broad Institute, Inc. Compositions, panels, and methods for characterizing chronic lymphocytic leukemia
JP2024540588A (ja) * 2021-11-18 2024-10-31 ランタン ファルマ インコーポレイテッド アシルフルベン及び放射線によるがんの治療方法
CN114113051B (zh) * 2021-12-16 2023-06-16 南京信息工程大学 一种psma电致化学发光传感器的制备方法及应用
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN114480639B (zh) * 2021-12-24 2022-09-30 中国医学科学院北京协和医院 新靶点用于诊断和治疗垂体腺瘤
WO2023143608A1 (zh) * 2022-01-30 2023-08-03 上海复东生物医药有限责任公司 一种组合物、其制备方法及应用
CN114518456B (zh) * 2022-02-17 2025-06-20 南京医科大学 一种通过diaph1蛋白预测肿瘤免疫治疗疗效的方法及试剂盒
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143255B2 (en) * 2005-11-16 2012-03-27 S*Bio Pte Ltd. Heteroalkyl linked pyrimidine derivatives

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US9120815B2 (en) * 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
JP2015524394A (ja) * 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
EP2981252A4 (en) * 2013-04-04 2017-02-22 Olivia Newton-John Cancer Research Institute Methods of treating diseases characterized by excessive wnt signalling
EP3010918B1 (en) * 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
CA2920113A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
AU2014368927B2 (en) * 2013-12-20 2018-10-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
CA2944727A1 (en) * 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
CN106536507B (zh) 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143255B2 (en) * 2005-11-16 2012-03-27 S*Bio Pte Ltd. Heteroalkyl linked pyrimidine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOFMEISTER ET AL.: "TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients", BLOOD, vol. 126, 2015, pages 3052, XP055424385. GOH ET AL.: "TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti- leukemic properties", LEUKEMIA, vol. 26, 23 August 2011 (2011-08-23), pages 236 - 243, XP055071412, реферат. *
HOFMEISTER, ET AL.: "TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients | Blood Journal", BLOOD, vol. 126, 1 January 2015 (2015-01-01), XP055424385 *

Also Published As

Publication number Publication date
MX2021012977A (es) 2022-10-03
JP2022050631A (ja) 2022-03-30
KR20190006948A (ko) 2019-01-21
WO2017165732A1 (en) 2017-09-28
ES2941687T3 (es) 2023-05-24
IL261959B1 (en) 2023-04-01
KR102491013B1 (ko) 2023-01-31
EP3432888A1 (en) 2019-01-30
SG10202005621WA (en) 2020-07-29
IL261959A (en) 2018-10-31
CA3018875A1 (en) 2017-09-28
US11865116B2 (en) 2024-01-09
NZ746933A (en) 2025-03-28
AU2017238647A1 (en) 2018-10-25
JP7459149B2 (ja) 2024-04-01
SG11201808306PA (en) 2018-10-30
CN115969854A (zh) 2023-04-18
RU2018137217A (ru) 2020-04-24
US20200323862A1 (en) 2020-10-15
MX2022008868A (es) 2022-08-11
EP3432888B1 (en) 2022-10-05
EP3432888A4 (en) 2019-11-13
JP2019509354A (ja) 2019-04-04
US20240156824A1 (en) 2024-05-16
CN109195603A (zh) 2019-01-11
AU2017238647B2 (en) 2021-12-09
CN109195603B (zh) 2022-11-08
CN115969854B (zh) 2025-12-23
RU2018137217A3 (https=) 2020-05-29
IL261959B2 (en) 2023-08-01
KR20230020549A (ko) 2023-02-10
JP7026299B2 (ja) 2022-02-28
MX387283B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
US20240156824A1 (en) Treatment of cancer with tg02
US20240254141A1 (en) Polymorphic form of tg02 for treating cancer
EP3430171B1 (en) Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
ES2785033T3 (es) Uso de PDCD1LG1 y CXCL9 como marcadores para el pronóstico del cáncer
ES2808004T3 (es) Métodos para clasificar pacientes con un cáncer sólido
Chen et al. Li u Y
Danaher et al. Single cell spatial transcriptomic profiling of childhood-onset lupus nephritis reveals complex interactions between kidney stroma and infiltrating immune cells
US20220170940A1 (en) Biomarker with therapeutic implications for peritoneal carcinomatosis
Zhang et al. Unraveling the Microenvironment and the Pathogenic Axis of HIF‐1α–Visfatin–Fibrosis in Autoimmune Pancreatitis Using a Single‐Cell Atlas
CA3018875C (en) Treatment of cancer with tg02
US20240139175A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
HK40106713A (en) Polymorphic form of tg02
US20260112450A1 (en) Methods for selection of cancer patients for anti-angiogenic and immune checkpoint blockage therapies and combinations thereof
HK1261788B (en) Treatment of cancer with tg02
HK1261788A1 (en) Treatment of cancer with tg02
HK40025378B (en) Polymorphic form of tg02
HK40025378A (en) Polymorphic form of tg02
EP3974541A1 (en) Composition for cancer diagnosis
Kurimoto et al. MYC/BCL2 double-hit Lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment
Zhang Bioinformatic Analysis of Acute Respiratory Distress Syndrome and Sepsis Reveals Hypoxia Related Genes
Voth Park Exploiting Multi-Cell Type Cultures to Elucidate Tumor Cell Features That Impact Macrophage Phenotype
Li et al. Quercetin Induces Ferroptosis in Ovarian Cancer by Suppressing the NRF2/HO-1/GPX4 Axis and Increasing the Efficacy of Cisplatin